ARWR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arrowhead Pharmaceuticals Inc (ARWR) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has promising developments in its obesity pipeline and favorable long-term catalysts, the recent price trend, lack of immediate trading signals, and mixed financial performance suggest that it is better to monitor the stock for a more favorable entry point.
The stock is trading below its previous close with a -2.30% regular market change and a -1.67% pre-market change. The RSI is neutral at 46.987, and the MACD is positive but contracting. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is near its pivot support level (S1: 61.479). Overall, the technical indicators suggest a neutral to slightly bearish short-term trend.
Promising obesity pipeline with positive siRNA-INHBE data and Phase 1/2a results.
Analysts have raised price targets significantly, with some targets as high as $
Broad pipeline execution with multiple readouts expected later this year, including key Phase 3 SHTG data in Q3.
Recent price decline of -2.30% in the regular market and -1.67% in pre-market trading.
Mixed financial performance, with revenue increasing significantly YoY but net income and EPS dropping sharply.
Analysts like Morgan Stanley maintain an Equal Weight rating, suggesting cautious optimism.
In Q1 2026, revenue surged 10461.32% YoY to $264.03 million, but net income dropped -117.80% YoY to $30.81 million, and EPS fell -115.83% YoY to 0.22. Gross margin remained stable at 100%. While revenue growth is impressive, profitability metrics are concerning.
Analysts are mixed but leaning positive. Recent upgrades include price targets of $101 (B. Riley) and $100 (H.C. Wainwright), citing promising obesity data and long-term growth potential. However, Morgan Stanley maintains an Equal Weight rating with a lowered price target of $78, reflecting cautious optimism.
